TY - JOUR
T1 - Other compounds and targets in non-small cell lung cancer
AU - Villaflor, Victoria
AU - Bonomi, Philip
N1 - Funding Information:
Dr Villaflor owns stock in Abbott, Amgen, Astra-Zeneca, Bristol-Myers Squibb, Genentech Inc, and Pfizer. Dr Bonomi has served on the speakers’ bureau for Eli Lilly Genentech Inc, and OSI. He has received research grant support from Eli Lilly, Genentech Inc, OSI, Bristol-Myers Squibb, Pfizer, AstraZeneca, Human Genome Science, Imclone, EMD Pharmaceuticals, Cell Therapeutics Inc, and Celgene.
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2005/12
Y1 - 2005/12
N2 - It has become increasingly apparent in recent years that a therapeutic plateau has been reached for patients with advanced stage non-small cell lung cancer (NSCLC) treated with conventional cytotoxic agents. As a result, investigators have directed their efforts toward the development of treatments encompassing novel targeted agents. Apoptosis is one of many cellular pathways currently under investigation as a therapeutic target for the treatment of NSCLC. Anti-inflammatory agents, including cyclooxygenase inhibitors, have been shown to inhibit apoptosis and appear promising based on preclinical studies. However, several phase II studies indicate that this therapeutic strategy is unlikely to be successful. In contrast, the proteosome inhibitor bortezomib has shown promise in preliminary studies, and further efforts to elucidate the role this agent may play in the treatment of NSCLC are ongoing. Agonists of the tumor necrosis factor-related, apoptosis-inducing ligand have also entered into early clinical studies in patients with NSCLC. Further studies will be needed to fully clarify how agents targeting the apoptotic pathway can be used in the treatment of NSCLC, but the results of current clinical trials suggest that certain agents may be active.
AB - It has become increasingly apparent in recent years that a therapeutic plateau has been reached for patients with advanced stage non-small cell lung cancer (NSCLC) treated with conventional cytotoxic agents. As a result, investigators have directed their efforts toward the development of treatments encompassing novel targeted agents. Apoptosis is one of many cellular pathways currently under investigation as a therapeutic target for the treatment of NSCLC. Anti-inflammatory agents, including cyclooxygenase inhibitors, have been shown to inhibit apoptosis and appear promising based on preclinical studies. However, several phase II studies indicate that this therapeutic strategy is unlikely to be successful. In contrast, the proteosome inhibitor bortezomib has shown promise in preliminary studies, and further efforts to elucidate the role this agent may play in the treatment of NSCLC are ongoing. Agonists of the tumor necrosis factor-related, apoptosis-inducing ligand have also entered into early clinical studies in patients with NSCLC. Further studies will be needed to fully clarify how agents targeting the apoptotic pathway can be used in the treatment of NSCLC, but the results of current clinical trials suggest that certain agents may be active.
UR - http://www.scopus.com/inward/record.url?scp=31744449431&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=31744449431&partnerID=8YFLogxK
U2 - 10.1053/j.seminoncol.2005.10.001
DO - 10.1053/j.seminoncol.2005.10.001
M3 - Article
C2 - 16459177
AN - SCOPUS:31744449431
SN - 0093-7754
VL - 32
SP - 30
EP - 36
JO - Seminars in Oncology
JF - Seminars in Oncology
IS - SUPPL. 10
ER -